Evidence map›Paper›PMID 38486043›Full record

ArticleScientific reports2024

Enterobacter asburiae ST229: an emerging carbapenemases producer.

Vittoria Mattioni Marchetti, Angela Kuka, Aurora Piazza, Stefano Gaiarsa, Cristina Merla, Mariangela Sottosanti, Patrizia Cambieri, Roberta Migliavacca, Fausto Baldanti

Erratum issuedOpen access · goldAbstract readCase Reports
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Vittoria Mattioni Marchetti *Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.
Angela Kuka *Microbiology and Virology Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Aurora PiazzaDepartment of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy. aurora.piazza@unipv.it.
Stefano GaiarsaMicrobiology and Virology Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Cristina MerlaMicrobiology and Virology Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Mariangela SottosantiUnit of Anaesthesia and Intensive Care II, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Patrizia CambieriMicrobiology and Virology Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Roberta MigliavaccaDepartment of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.
Fausto BaldantiDepartment of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.
University of Pavia · ITPoliclinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterobacter asburiae, member of the Enterobacter cloacae complex (ECC) group, shows an increasing clinical relevance being responsible for infections like pneumonia, urinary tract infections and septicemia. The aim of the present study was the investigation of the genomic features of two XDR E. asburiae ST229 clinical strains co-carrying blaNDM-1 and blaVIM-1 determinants, collected in October 2021 and in June 2022, respectively. Two E. asburiae strains were collected from rectal swabs of as many patients admitted to the cardiopulmonary intensive care unit of Fondazione I.R.C.C.S. "Policlinico San Matteo" in Pavia, Italy. Based on the antibiotic susceptibility profile results, both isolates showed an XDR phenotype, retaining susceptibility only to fluoroquinolones. Both isolates shared identical resistome, virulome, plasmid content, and belonged to ST229, a rarely reported sequence type. They co-harbored blaNDM-1 and blaVIM-1 genes, that resulted located on transferable plasmids by conjugation and transformation. Moreover, both strains differed in 24 SNPs and showed genetic relatedness with E. asburiae ST709 and ST27. We described the first case of ST229 E. asburiae co-harboring blaNDM-1 and blaVIM-1 in Italy. This study points out the emergence of carbapenemases in low-risk pathogens, representing a novel challenge for public health, that should include such types of strains in dedicated surveillance programs. Antimicrobial susceptibility testing was carried out using Thermo Scientific™ Sensititre™ Gram Negative MIC Plates DKMGN. Both strains underwent whole-genome sequencing (WGS) using Illumina Miseq platform. Resistome, plasmidome, virulome, MLST, plasmid MLST and a SNPs-based phylogenetic tree were in silico determined.

Indexed as

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesEnterobacterEuropean PeopleHumansMultilocus Sequence TypingPhylogenyAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasescarbapenemaseCarbapenemase-producingEnterobacter asburiaeEpidemiologyLow-risk pathogensNDM-1SurveillanceVIM-1WGS

Identifiers

PMID38486043
PMCPMC10940580
OpenAlexW4392818447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.